TAK
Takeda Pharmaceutical Co Ltd ADR
NYSE: TAK · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$20.15
-0.59% today
Updated 2026-10-28
Market cap
$64.66B
P/E ratio
—
P/S ratio
0.01x
EPS (TTM)
$-0.34
Dividend yield
3.05%
52W range
$13 – $21
Volume
2.5M
Takeda Pharmaceutical Co Ltd ADR (TAK) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
—
Last 8 quarters
Avg EPS surprise
—
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
—
Most recent quarter
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $119.00 | $4630.0B | +1.1% | 17 | medium |
| 2027 (E) | $165.00 | $4850.0B | +4.8% | 17 | medium |
| 2028 (E) | $210.00 | $5180.0B | +6.8% | 17 | medium |
| 2029 (E) | $255.00 | $5520.0B | +6.6% | 17 | low |
| 2030 (E) | $305.00 | $5890.0B | +6.7% | 17 | low |
Frequently asked questions
What is the expected EPS for TAK next fiscal year?
Analysts expect Takeda Pharmaceutical Co Ltd ADR to earn about $119.00 per share next fiscal year, on revenue of $4.63T, from 17 analysts. Forward estimates matter because today's price is justified by future earnings, not trailing ones.
What are TAK's longer-term earnings estimates?
Consensus sees EPS reaching about $305.00 by 2030, on roughly $5.89T of revenue. Longer-dated estimates carry lower confidence but frame the growth runway the current valuation leans on.